journal
MENU ▼
Read by QxMD icon Read
search

Journal of the National Comprehensive Cancer Network: JNCCN

journal
https://www.readbyqxmd.com/read/30546001/reviewer-page
#1
(no author information available yet)
No abstract text is available yet for this article.
December 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30546000/oncology-research-program
#2
(no author information available yet)
No abstract text is available yet for this article.
December 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30545999/anti-egfr-therapy-in-right-sided-metastatic-colorectal-cancer-right-or-wrong
#3
Benjamin A Weinberg
No abstract text is available yet for this article.
December 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30545998/do-all-patients-with-polycythemia-vera-or-essential-thrombocythemia-need-cytoreduction
#4
REVIEW
Kamya Sankar, Brady L Stein
Polycythemia vera (PV) and essential thrombocythemia (ET) are Philadelphia chromosome-negative chronic myeloproliferative neoplasms (MPNs), characterized by expansion of normal blood counts, bleeding, thrombosis, and the potential for transformation to myelofibrosis (MF) or acute myeloid leukemia (AML). The primary goals of treatment for MPNs are to reduce the risk of thrombosis, alleviate systemic symptom burden (eg, fatigue, pruritus, microvascular symptoms, and symptomatic splenomegaly), and to prevent transformation to MF/AML...
December 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30545997/systemic-mastocytosis-version-2-2019-nccn-clinical-practice-guidelines-in-oncology
#5
Jason Gotlib, Aaron T Gerds, Prithviraj Bose, Mariana C Castells, Michael W Deininger, Ivana Gojo, Krishna Gundabolu, Gabriela Hobbs, Catriona Jamieson, Brandon McMahon, Sanjay R Mohan, Vivian Oehler, Stephen Oh, Eric Padron, Philip Pancari, Nikolaos Papadantonakis, Animesh Pardanani, Nikolai Podoltsev, Raajit Rampal, Erik Ranheim, Lindsay Rein, David S Snyder, Brady L Stein, Moshe Talpaz, Swapna Thota, Martha Wadleigh, Katherine Walsh, Mary Anne Bergman, Hema Sundar
Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocytosis diagnosed in adults, characterized by mast cell infiltration of one or more extracutaneous organs (with or without skin involvement). The identification of KIT D816V mutation and the emergence of novel targeted therapies have significantly improved the diagnosis and treatment of systemic mastocytosis...
December 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30545996/variation-in-integrated-head-and-neck-cancer-care-impact-of-patient-and-hospital-characteristics
#6
Lydia F J van Overveld, Robert P Takes, Jozé C C Braspenning, Robert J Baatenburg de Jong, Jan P de Boer, John J A Brouns, Rolf J Bun, Eric A Dik, Boukje A C van Dijk, Robert J J van Es, Frank J P Hoebers, Barry Kolenaar, Arvid Kropveld, Ton P M Langeveld, Hendrik P Verschuur, Jan G A M de Visscher, Stijn van Weert, Max J H Witjes, Ludi E Smeele, Matthias A W Merkx, Rosella P M G Hermens
Background: Monitoring and effectively improving oncologic integrated care requires dashboard information based on quality registrations. The dashboard includes evidence-based quality indicators (QIs) that measure quality of care. This study aimed to assess the quality of current integrated head and neck cancer care with QIs, the variation between Dutch hospitals, and the influence of patient and hospital characteristics. Methods: Previously, 39 QIs were developed with input from medical specialists, allied health professionals, and patients' perspectives...
December 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30545995/impact-of-patient-and-clinician-reported-cumulative-toxicity-on-quality-of-life-in-patients-with-metastatic-castration-na%C3%A3-ve-prostate-cancer
#7
Claudia S E W Schuurhuizen, Patricia Marino, Annemarie M J Braamse, Laurien M Buffart, Florence Joly, Karim Fizazi, Muriel Habibian, Jean-Marie Boher, Michel Soulie, Stéphane Oudard, Inge R H M Konings, Henk M W Verheul, Joost Dekker, Gwenaelle Gravis
Background: Current toxicity evaluation is primarily focused on high-grade adverse events (AEs) reported by clinicians. However, the cumulative effect of multiple lower-grade AEs may also impact patients' quality of life (QoL). Further, patient-reported toxicity may be more representative of patients' treatment experiences. This study aimed to determine whether cumulative toxicity comprising all-grade AEs is more associated with QoL than cumulative toxicity comprising high-grade AEs only, and whether patient-reported cumulative toxicity is more associated with QoL than clinician-reported cumulative toxicity...
December 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30545994/comparison-of-overall-survival-between-preoperative-chemotherapy-and-chemoradiotherapy-for-resectable-pancreatic-adenocarcinoma
#8
Ali A Mokdad, Rebecca M Minter, Adam C Yopp, Matthew R Porembka, Sam C Wang, Hong Zhu, Mathew M Augustine, John C Mansour, Michael A Choti, Patricio M Polanco
Background: Preoperative therapy is being increasingly used in the treatment of resectable pancreatic cancer. Because there are only limited data on the optimal preoperative regimen, we compared overall survival (OS) between preoperative chemotherapy (CT) and preoperative chemoradiotherapy (CRT) in resectable pancreatic adenocarcinoma. Patients and Methods: Patients receiving preoperative therapy and resection for clinical T1-3N0-1M0 adenocarcinoma of the pancreas were identified in the National Cancer Database for 2006 through 2012...
December 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30545993/new-cancer-drug-approvals-from-the-perspective-of-a-universal-healthcare-system-analyses-of-the-pan-canadian-oncology-drug-review-recommendations
#9
Saroj Niraula, Zoann Nugent
Background: FDA approvals do not consider cost, but they set the tone for regulatory approvals worldwide, including in countries with universal healthcare where cost-effectiveness, utility, and adoption feasibility are considered rigorously. Methods: Data from the pan-Canadian Oncology Drug Review (pCODR), a national drug review system that makes evidence-based funding recommendations to Canada's provinces and territories, were collected. Our objectives were to assess (1) temporal trends in cost and efficacy of drugs reviewed, (2) correlations among magnitude of benefits, cost, and pCODR decisions, and (3) predictors of approvals...
December 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30545992/delays-in-diagnosis-and-treatment-of-breast-cancer-a-safety-net-population-profile
#10
Kshama Jaiswal, Madelyne Hull, Anna L Furniss, Reina Doyle, Natalia Gayou, Elizabeth Bayliss
Background: Timely detection and treatment of breast cancer is important in optimizing survival and minimizing recurrence. Given disparities in breast cancer outcomes based on socioeconomic status, we examined time to diagnosis and treatment in a safety-net hospital. Methods : We conducted a retrospective review of all patients with breast cancer diagnosed between July 1, 2010, and June 30, 2012 (N=120). We limited our analytic sample to patients with nonrecurrent, primary stage 0-III breast cancer (N=105) and determined intervals from presentation to diagnosis, diagnosis to first treatment, last surgery to chemotherapy initiation, and last surgery to start of radiation therapy (RT)...
December 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30545991/metastatic-bulk-independently-predicts-outcomes-for-egfr-precision-targeting-in-colorectal-cancer
#11
Jeremy D Kratz, Nataliya V Uboha, Sam J Lubner, Daniel L Mulkerin, Linda Clipson, Yanyao Yi, Menggang Yu, Kristina A Matkowskyj, Noelle K LoConte, Dustin A Deming
Background: Molecular profiles guide the clinical management of metastatic colorectal cancer (mCRC), particularly related to the use of anti-epidermal growth factor receptor (EGFR) antibodies. Tumor sidedness has also been implicated in resistance to these therapies, but has largely been studied in the first-line setting. We examined the role of tumor sidedness and disease bulk in predicting clinical outcomes to anti-EGFR therapy in the treatment-refractory setting. Methods: We identified a retrospective cohort of 62 patients with KRAS wild-type mCRC who received anti-EGFR therapy in the late-line setting...
December 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30545990/nccn-guidelines-insights-thyroid-carcinoma-version-2-2018
#12
Robert I Haddad, Christian Nasr, Lindsay Bischoff, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Whitney Goldner, Megan Haymart, Carl Hoh, Jason P Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M Lamonica, Bryan McIver, Christopher D Raeburn, John A Ridge, Matthew D Ringel, Randall P Scheri, Jatin P Shah, Rebecca Sippel, Robert C Smallridge, Cord Sturgeon, Thomas N Wang, Lori J Wirth, Richard J Wong, Alyse Johnson-Chilla, Karin G Hoffmann, Lisa A Gurski
The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E-mutated anaplastic thyroid carcinoma...
December 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30545989/pathologic-complete-response-in-a-large-gastric-gist-using-molecular-markers-to-achieve-maximal-response-to-neoadjuvant-imatinib
#13
Joshua B Brown, Reetesh K Pai, Melissa A Burgess, Jennifer Chennat, Amer H Zureikat
Gastrointestinal stromal tumors (GISTs) represent 1% of alimentary tract neoplasms. Up to 90% of GISTs are driven by activating mutations in tyrosine kinase KIT or PDGFR α genes. Imatinib mesylate is a tyrosine kinase inhibitor that has recently been used in a neoadjuvant role for locally advanced GIST. Pathologic complete response (pCR) to imatinib, however, is rare and may be limited to patients with certain mutations. We report on a 71-year-old woman with a large advanced gastric GIST near the gastroesophageal junction initially involving the pancreas, spleen, adrenal, and aortic wall...
December 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30545988/in-memoriam-arti-hurria-md
#14
June M McKoy
No abstract text is available yet for this article.
December 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30545987/letter-to-the-editor-could-immunogenicity-of-kaposi-sarcoma-be-more-linked-to-viral-antigens-than-to-the-tumor-mutational-burden
#15
LETTER
Julie Delyon, Dimitri Arangalage, Barouyr Baroudjian, Celeste Lebbe, Andrew S Brohl, James Saller
No abstract text is available yet for this article.
December 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30545986/an-oncologist-s-letter-to-santa-bring-me-drugs
#16
Margaret Tempero
No abstract text is available yet for this article.
December 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30538108/use-of-novel-combination-therapies-in-the-treatment-of-advanced-hr-her2-breast-cancer
#17
(no author information available yet)
Endocrine therapy remains the backbone for treatment of hormone receptor-positive breast cancer in the metastatic setting. Despite the effectiveness of endocrine therapy, primary and acquired endocrine resistance continue to be important clinical challenges. The landscape of metastatic breast cancer treatment has changed considerably with the incorporation of novel agents, including cyclin-dependent kinase 4/6 and mammalian target of rapamycin inhibitors. This article reviews current endocrine treatment strategies and recent and ongoing studies of combination therapies in metastatic hormone receptor-positive, HER2-negative breast cancer...
December 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30442739/electronic-clinical-decision-tools-for-improving-adherence-to-colon-cancer-surveillance-guidelines-can-the-chips-finally-fall-into-place
#18
Shajan Peter
No abstract text is available yet for this article.
November 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30442738/screening-mammography-for-average-risk-women-the-controversy-and-nccn-s-position
#19
REVIEW
Mark A Helvie, Therese B Bevers
Breast cancer remains the most common nonskin cancer among women and a leading cause of morbidity and mortality. Early detection through screening and advances in treatment have contributed to a 39% mortality reduction in the United States since 1990. The NCCN Guidelines for Breast Cancer Screening and Diagnosis recommend annual mammographic screening for average-risk women beginning at age 40 years. Mammographic screening and subsequent treatment reduces breast cancer mortality based on a wide range of studies...
November 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30442737/diagnosis-and-management-of-high-risk-breast-lesions
#20
REVIEW
Parijatham S Thomas
Atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS) are nonmalignant breast lesions that confer a 4- to 10-fold increased risk for breast cancer in women. Often, AH and LCIS are diagnosed through breast biopsy due to a mammographic or palpable finding. Although AH and LCIS are benign breast disease, further management is necessary due to their high-risk nature and premalignant potential. Over the decades, management of AH and LCIS has changed as more is learned about these disease processes. This review explores the studies evaluating the risk for breast cancer in women with AH or LCIS and the clinical management of these lesions, which can include a combination of surgical excision, surveillance, and risk-reduction therapy...
November 2018: Journal of the National Comprehensive Cancer Network: JNCCN
journal
journal
40348
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"